Correlation Between CA 15-3 And Miller Payne Histopathological Response In Locally Advanced Breast Cancer Undergoing FAC Regiment Neoadjuvant Chemotherapy

Kiki Akhmad Rizki, Raden Yohana Azhar, Birgitta Dewayani, Aulia Novariza Fahman

Abstract


Response to chemotherapy for breast cancer can be assessed using the CA 15-3 tumor marker, or through histopathological means such as Miller Payne assessment. This study aimed to explore the correlation between CA 15-3 level and histopathological response in locally advanced breast cancer. This is a cross-sectional study measuring CA 15-3 before and after neoadjuvant chemotherapy using the FAC regiment. This study took place in Dr. Hasan Sadikin Hospital Bandung, Indonesia, from January to August 2022. Data on histopathological responses before chemotherapy and after surgery were also collected. Thirty-nine patients were admitted as subjects. Most patients had invasive carcinoma of no special type (79.5%) and luminal B HER 2 molecular subtype (38.5%). A significant decrease in CA 15-3 level after chemotherapy (from 23.54±18.38 ng/ml to 16.30±6.51 ng/mL) was observed. No significant correlation between CA 15-3 level and Miller Payne histopathological responses were found in the subjects.

Keywords


Breast cancer, chemotherapy, histopathology

Full Text:

PDF

References


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. doi:10.3322/caac.21660
  2. Purwanto, Heru HD, Arief HW. Panduan Penatalaksanaan Kanker Payudara. Jakarta: PERABOI; 2014. p. 9–84
  3. Proskurina AS, Kupina VV, Efremov YR, Dolgova EV, Ruzanova VS, Ritter GS, et al. Karanahan: a potential new treatment option for human breast cancer and its validation in a clinical setting. Breast Cancer (Auckl). 2022;16:11782234211059931. doi:10.1177/11782234211059931
  4. Zelig U, Barlev E, Bar O, Gross I, Flomen F, Mordechai S, et al. Early detection of breast cancer using total biochemical analysis of peripheral blood components: a preliminary study. BMC Cancer. 2015;15(1):408. doi:10.1186/s12885-015-1414-7
  5. Fakhari A, Gharepapagh E, Dabiri S, Gilani N. Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients. Med J Islam Repub Iran. 2019;33:142. doi:10.34171/mjiri.33.142
  6. Moghbeli M. Genetic and molecular biology of breast cancer among Iranian patients. J Transl Med. 2019;17(1):218. doi:10.1186/s12967-019-1968-2
  7. Shintia C, Endang H, Diani K. Assessment of pathological response to neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL. Malays J Pathol. 2016;38(1):25-32.
  8. Liu X, Yang X, Wu Q, Zhang T, Jiang D, Wang Z. Can patients with good tumor regression grading after neoadjuvant chemoradiotherapy be exempted from lateral lymph node dissection?. Discov Oncol. 2022;13(1):144. doi:10.1007/s12672-022-00607-w
  9. Harris JR, Lippman ME, Morrow M, Osborne CK. Disease of the Breast. Evaluation After Primary Therapy and Management of Reccurent Breast Cancer. Ann Surg. 2014;67:871.
  10. Baun C, Falch K, Gerke O, Hansen J, Nguyen T, Alavi A, et al. Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer. BMC Med Imaging. 2018;18(1):11. doi:10.1186/s12880-018-0254-8
  11. Yang Y, Zhang H, Zhang M, Meng Q, Cai L, Zhang Q. Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients. Oncol Lett. 2017;14(6):7549–56.
  12. Hasan D. Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients. J Circ Biomark. 2022;11:57-63. doi:10.33393/jcb.2022.2446
  13. Jia L, Li G, Ma N, Zhang A, Zhou Y, Ren L, et al. Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction. BMC Cancer. 2022;22(1):760. doi:10.1186/s12885-022-09864-y
  14. Chin YM, Shibayama T, Chan HT, Otaki M, Hara F, Kobayashi T, et al. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Sci. 2022;113(5):1808–20. doi:10.1111/cas.15304
  15. Sottotetti F, Ferraris E, Tagliaferri B, Palumbo R, Quaquarini E, Teragni C, et al. The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors. Drugs Context. 2022;11:2022-1-3. doi:10.7573/dic.2022-1-3
  16. Purnomo E, Hidayat B, Kartamihardja A, Tanumihardjo M, Masjhur J. Signifikansi Dari Korelasi Uji Penanda Tumor CEA, CA 15-3 Dengan Sidik Tulang Pada Pasien Kanker Payudara. [Internet] 2005 [cited on 2022 March 21]. Available from: http://pustaka.unpad.ac.id/wp-content/uploads/2009/05/signifikansi_dari_korelasi_uji_petanda.pdf.
  17. Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One. 2015;10(7):e0133830. doi:10.1371/journal.pone.0133830
  18. Araz M, Beypinar I, Kazan S, Inci F, Celiker M, Uysal M. Are preoperative serum CA15-3 levels different in breast cancer subgroups?. Curr Probl Cancer. 2019;43(2):115–22.
  19. Gupta SK, Kumar V, Anees A, Goel A. The study of prognostic significance of CA 15-3 in breast cancer. Int Surg J. 2018;5(2):580. doi:10.18203/2349-2902.isj20180356
  20. Lin X, Xu R, Mao S, Zhang Y, Dai Y, Guo Q, et al. Metabolic biomarker signature for predicting the effect of neoadjuvant chemotherapy of breast cancer. Ann Transl Med. 2019;7(22):670. doi:10.21037/atm.2019.10.34




DOI: https://doi.org/10.15395/mkb.v56.3145

Article Metrics

Abstract view : 416 times
PDF - 191 times

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


 


Creative Commons License
MKB is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats